bMembers of the genus Acanthamoeba are facultative pathogens of humans, causing a sight-threatening keratitis and a fatal encephalitis. We have targeted myosin-IC by using small interfering RNA (siRNA) silencing as a therapeutic approach, since it is known that the function of this protein is vital for the amoeba. In this work, specific siRNAs against the Acanthamoeba myosin-IC gene were developed. Treated and control amoebae were cultured in growth and encystment media to evaluate the induced effects after myosin-IC gene knockdown, as we have anticipated that cyst formation may be impaired. The effects of myosin-IC gene silencing were inhibition of cyst formation, inhibition of completion of cytokinesis, inhibition of osmoregulation under osmotic stress conditions, and death of the amoebae. The finding that myosin-IC silencing caused incompletion of cytokinesis is in agreement with earlier suggestions that the protein plays a role in cell locomotion, which is necessary to pull daughter cells apart after mitosis in a process known as "traction-mediated cytokinesis". We conclude that myosin-IC is a very promising potential drug target for the development of much-needed antiamoebal drugs and that it should be further exploited for Acanthamoeba therapy.A canthamoeba is a genus of small amoebae that are ubiquitous in the human environment. They alternate between feeding moving trophozoites and, when conditions are unfavorable, a resting cyst stage. Members of this genus are facultative human pathogens that cause the serious eye infection Acanthamoeba keratitis and a rare but usually fatal infection known as granulomatous Acanthamoeba encephalitis (1). The fact that this organism is able to form a highly resistant cyst stage is a significant clinical problem since it is extremely resilient when exposed to many disinfectants, antibiotics, and even acids (2). The persistence of the cyst stage after cessation of therapies that are effective against the growing amoebae can cause reinfection (3). Specific drugs that are capable of eliminating the amoebae rapidly enough to prevent cyst formation are urgently required. The search for therapeutic targets is currently focused on processes that are unique to the amoebic biological processes. To this end, we have selected the motor protein myosin-IC, as it performs a function in amoebae that human myosin-IC lacks. The myosin-IC family proteins are single-headed myosins that were first identified and characterized in a strain of Acanthamoeba (4). Following their discovery in Acanthamoeba, this family of proteins was also found in other organisms, including humans (5). Acanthamoeba myosin-IC has been shown to be essential for the contraction of the contractile vacuole, an organelle unique to these protozoa that functions as a water pump to maintain osmotic balance. Furthermore, inhibition of this motor protein by antibodies prevents the vacuole from excreting excess water so the amoeba explodes (6). Therefore, Acanthamoeba myosin-IC is a promising therapeutic target, as it is ver...